关键词: 强骨饮, 骨质疏松, 骨密度

Abstract: Objective To observe and evaluate the clinical efficacy and safety of the Qiangguyin on postmenopausal osteoporosis(PMOP), and to explore its mechanism. Methods All 90 patients who meet the inclusion criteria were randomly divided into three groups, namely Qiangguyin group, basic medication group and Xianlinggubao group with 30 cases for each one. Basic medication group was given calcium carbonate D3 tablets and alfacalcidol capsules. Xianlinggubao group was based on basic medication group to plus Xianlinggubao capsules. Qiangguyin group was based on basic medication group to plus Qiangguyin granules. All groups were treated for 6 months. Outcome measures included bone mineral density(BMD), bone metabolic markers, visual analogue scales(VAS) and SF-36 score. Results After 6 months of treatment, VAS and SF-36 scores of all groups had changes, the difference was statistically significant(P <0.05). BMD and bone metabolic markers of Qiangguyin group and Xianlinggubao group after treatment changed, both the groups had advantages over basic medication group (P<0.05). Conclusion Qiangguyin is not only able to effectively relieve pain of PMOP, but also promote the bone mineral density. It may improve the quality of life and reduce the bone metabolic markers (PINP and S-CTX).